This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardiovascular Systems (CSII) Stock Hits New 52-Week High
by Zacks Equity Research
Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.
IDEXX Launches Cytology Service to Upgrade Veterinary Care
by Zacks Equity Research
IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.
Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Hologic (HOLX) gains from several positive developments.
Boston Scientific Gets a Boost From New Products, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
by Zacks Equity Research
Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.
NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show
by Zacks Equity Research
NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.
Globus Medical Gains From International Spine Arm, Innovation
by Zacks Equity Research
Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.
Integra Announces Preliminary Q4 Results, Share Buyback Plan
by Zacks Equity Research
Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.
Boston Scientific Stock Dips on Dull Preliminary Q4 Results
by Zacks Equity Research
Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now
by Zacks Equity Research
Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.
LabCorp Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
LabCorp (LH) is optimistic about maintaining its growth momentum on several recent developments.
CVS Health's Selling Seasons Strong, Omnicare Arm Upsets
by Zacks Equity Research
CVS Health's (CVS) 2020 PBM selling season remains strong with gross new business and net new business wins.
Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan
by Zacks Equity Research
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
Thermo Fisher Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about maintaining its growth momentum on several recent developments.
Medtronic's Neurostimulator DBS System Receives CE Mark
by Zacks Equity Research
Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.
Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift
by Zacks Equity Research
Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.
Globus Medical Stock Up on Solid '19 Preliminary Results
by Zacks Equity Research
Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.
Medtronic (MDT) Buys Stimgenics, To Present New Trial Results
by Zacks Equity Research
Medtronic (MDT) acquires Stimgenics to integrate DTM therapy in its pain therapies segment. It will also present trial results favoring the therapy at the upcoming NANS meeting.
Varian (VAR) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Varian (VAR) gains from several positive developments.
Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod
by Zacks Equity Research
Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q3.
Amedisys Gains on Favorable Demography, New Hospice Buyouts
by Zacks Equity Research
Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.
Exact Sciences Rides on Cologuard, Eyes Merger Synergies
by Zacks Equity Research
Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.
Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
by Zacks Equity Research
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
Here's Why You Should Add STERIS (STE) to Portfolio Now
by Zacks Equity Research
Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.